Global 16/11/2021 RIEMSER BECOMES ESTEVE GERMANY WITH A NEW MANAGING DIRECTOR, KLAUS SCHWARZ RIEMSER Pharma GmbH has been part of the international pharma company ESTEVE since last year, and now officially becomes ESTEVE Pharmaceuticals GmbH: a different brand but the same innovative products and services. Germany is ESTEVE's flagship in the EU market Klaus Schwarz has been ESTEVE's Managing Director in Germany since September 2021 with the goal of positioning ESTEVE in Germany to integrate Riemser's positive image and its many years of experience in the German market into the new brand Klaus Schwarz has been heading ESTEVE in Germany for the past few months. He has many years of extensive experience in the pharmaceutical and medical technology sector, expertise in bringing medical products to market, a comprehensive understanding of healthcare and marketing as well as sales training techniques. After positions at leading pharma companies where he worked both nationally and internationally, Schwarz is now looking forward to his new professional challenge: "There is still a lot to do in specialized therapeutic areas. We want to add value and contribute to the preservation of the healthcare system through comprehensive solutions ranging from specialized medicine to support for doctors and patients. ESTEVE is committed to advancing in innovation to improve people's life, we want to become a reliable partner for doctors and patients and make a name for ourselves as an innovative employer in the industry. Together, this will allow us to build on our strengths." Riemser is now ESTEVE The acquisition of Riemser was an important step for ESTEVE in its drive to internationalize the business and thus become a leading player in the field of specialty therapeutics. Germany is the company's largest non-Spanish affiliate and plays a central role in this respect. RIEMSER Pharma GmbH has now officially become ESTEVE Pharmaceuticals GmbH to increase international brand coherence without losing its proximity to and focus on patients' needs in local markets. ESTEVE's vision is to be a benchmark company in the field of specialized medicine, with proprietary products that provide answers to patients' unmet medical needs, and with a global presence in key markets. ESTEVE Germany's portfolio includes prescription drugs for the treatment of serious diseases in the therapeutic areas of oncology, infectiology, neurology, cardiovascular, dermatology, and ophthalmology. A responsible and socially committed company ESTEVE has been serving healthcare for more than 90 years. Its corporate sustainability strategy is based on three key areas (environment, people and business) with the same focus: sustainability and care. ESTEVE is also committed to the 2030 Agenda and the Sustainable Development Goals. Its commitment to innovation has been clearly reflected in the recent approval of Seglentis® by the FDA (U.S. Food and Drug Administration). It is an innovative product comprising a co-crystal form of celecoxib (an anti-inflammatory) and tramadol (an analgesic) for the treatment of acute pain in adults.1-3 In the words of Klaus Schwarz: "Innovation and sustainability are key to our becoming a leading healthcare company because taking care of people, taking care of our patients' needs, is our raison d'être". References 1. Expert Opinion on Investigational Drugs. 2019;28(5):399-409. 2. Journal of Pain Research. 2019;12:2679-2689. 3. Crystal Growth & Design. 2017;17(4):1884-1892 and 2019;19(6):3172-3182. Share DOWNLOAD AS PDF Related Content 18/10/2021 ESTEVE ANNOUNCES FDA APPROVAL OF A NOVEL CO-CRYSTAL FORM OF CELECOXIB AND TRAMADOL FOR THE MANAGEMENT OF ACUTE PAIN Read more 14/10/2021 FOLLOWING IN THE WAKE OF COVID-19, MYOPIA WILL BE THE NEXT PANDEMIC TO EMERGE, ESPECIALLY AMONG CHILDREN AND YOUNG PEOPLE Read more 20/07/2021 ESTEVE QUIMICA ANNOUNCES AGREEMENT WITH SEAGEN TO PRODUCE TUCATINIB (TUKYSA®) Read more SEE MORE About us Who we are Corporate governance Our global presence Our commitment Therapeutic areas Contract Manufacturing R&D Research Areas Pipeline Scientific publications Patients B2B Partnering Media Corporate resources Contact Adverse reactions Work with us Privacy Legal notice Cookies policy Last update 11/11/2021 | © 1996-2021 ESTEVE Use of cookies We use our own and third-party cookies for analytic, technical and profiling purposes; we process data that is needed to create profiles based on your browsing habits. Press the "ACCEPT COOKIES" button to confirm their use. You can change the configuration of your cookies by pressing "MORE INFORMATION AND CONFIGURATION". ACCEPT COOKIES MORE INFORMATION AND CONFIGURATION * *This option allows you to reject the cookies.